<SEC-DOCUMENT>0001214659-22-005234.txt : 20220414
<SEC-HEADER>0001214659-22-005234.hdr.sgml : 20220414
<ACCEPTANCE-DATETIME>20220414143852
ACCESSION NUMBER:		0001214659-22-005234
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220414
DATE AS OF CHANGE:		20220414
EFFECTIVENESS DATE:		20220414

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		22826884

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tara Health Foundation
		CENTRAL INDEX KEY:			0001811207
		IRS NUMBER:				465645300
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		47 KEARNY STREET, #600
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94108
		BUSINESS PHONE:		6127014110

	MAIL ADDRESS:	
		STREET 1:		47 KEARNY STREET, #600
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94108
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>o414220px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">United States Securities and Exchange Commission<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXEMPT SOLICITATION<BR>
Pursuant to Rule 14a-103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of the Registrant: Pfizer Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of persons relying on exemption: Tara Health Foundation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address of persons relying on exemption: 47 Kearny Street, San Francisco,
CA 94108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated
under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, but is made voluntarily
in the interest of public disclosure and consideration of these important issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tara_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROXY MEMORANDUM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pfizer Inc. Shareholders</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RE:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item No. 5 (&ldquo;Report on Political Expenditures Congruency&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 12, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTACT:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shelley Alpern, Rhia Ventures at shelley&lt;at&gt;rhiaventures.org</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This is not a solicitation of authority to vote your proxy. Please
DO NOT send us your proxy card; Tara Health Foundation is not able to vote your proxies, nor does this communication contemplate such
an event. Tara Health Foundation urges shareholders to vote for Item No. 5 following the instructions provided on management's proxy
mailing. The cost of disseminating the foregoing information to shareholders is being entirely by Tara Health Foundation. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The foregoing information should not be construed as investment
advice. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tara Health Foundation urges shareholders to <B>vote YES</B> on of
Item No. 5 on the 2022 proxy ballot of Pfizer Inc. (&ldquo;Pfizer&rdquo; or &ldquo;the Company&rdquo;). The Resolved clause states:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Pfizer publish an annual report, at reasonable expense, analyzing
the congruency of political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values
and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have
led to a change in future expenditures or contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tara Health Foundation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tara Health Foundation aims to improve the health and well-being of
women and girls through the creative use of philanthropic capital. Our main areas of focus are reproductive and maternal health in the
United States, equitable workplaces, and gender lens impact investing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are long-term shareholders in Pfizer Inc. (&ldquo;Pfizer&rdquo;
or &ldquo;the Company&rdquo;). We support this shareholder proposal because it is apparent that many recipients of the Company&rsquo;s
political contributions are working actively to undermine access to its products, support policies that run contrary to some of Pfizer&rsquo;s
corporate responsibility initiatives, and in some cases, both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tara Health Foundation filed a proposal with the identical Resolved
clause in the 2021 proxy season, which received the support of 47.2% of votes cast. We are not the proponent of this year&rsquo;s proposal,
and it contains certain statements and arguments with which we disagree. Nevertheless, we believe that the report requested in the Resolved
clause would benefit shareholders, and if support drops below 15%, it will not be eligible for resubmission until 2026. The annual review
would institutionalize greater transparency and accountability in Pfizer&rsquo;s political spending process. This is too important to
be ineligible for shareholder input until 2026. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set forth below are our reasons for supporting Item No. 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Pfizer Political Contributions and the Incongruency Problem</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pfizer&rsquo;s political expenditures appear to be misaligned with
the Company&rsquo;s values and interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD><B>Pfizer is supporting champions of discredited 2020 election fraud conspiracy theories. </B>In January 2021, an internal Pfizer
memo communicated that the Company would not donate for at least 6 months to the 147 members of Congress who voted against certifying
the election results. Following that period, Pfizer resumed contributions and as of early April 2022, had contributed $74,000 to 31 politicians
within this group (https://www.accountable.us/corporate-donations-tracker/). <B><BR>
<BR>
</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD><B>Access to healthcare. </B>Pfizer has stated that &ldquo;Expanded access to health insurance coverage will help ensure that patients
with under-diagnosed and undertreated conditions are able to address them; and that those who will benefit from Pfizer medicines are better
able to have access to them.&rdquo; Yet the report <I>Conflicted Consequences</I> (Center for Political Accountability, 2020 at https://bit.ly/3f4DPa0,)
revealed that in 2018, Pfizer was a top contributor to a 527 organization that has been leading efforts to strike down the Affordable
Care Act, which has made prescription drugs more accessible for millions of Americans. (Organizations incorporated under Section 527 of
the IRS Code are devoted to election-related activity.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Pfizer manufactures several contraceptive products and a
drug commonly prescribed for use as an abortifacient. However:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on publicly available data analyzed by the Sustainable Investments
Institute (Si2), we estimate that in the 2016-2020 cycles, Pfizer and its employee PACs have made political donations totaling at least
$8.4 million to state and federal politicians and political organizations working to weaken women&rsquo;s access to reproductive health
care (data available upon request).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">According to the same source, Pfizer is one of 17 companies that donated
more than $100,000 each to the sponsors of state-level abortion restrictions in 2021. This included $42,000 to the sponsors of Texas&rsquo;s
landmark SB 8, which broke new ground by authorizing private citizens anywhere in the United States to claim a $10,000 bounty in return
enforcing the state&rsquo;s 6-week abortion.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In the 2022 election cycle (to date), Pfizer has contributed more than $200,000
to federal lawmakers who voted against the Women&rsquo;s Health Protection Act in February 2022 (OpenSecrets at https://bit.ly/3uoQcoT
and https://clerk.house.gov/Votes/2021295).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Conflicted Consequences </I>notes that Pfizer was a top contributor to
a 527 organization that funds state legislators&rsquo; efforts to implement extreme anti-abortion measures (https://bit.ly/3f4DPa0).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A soon-to-be-released survey from Morning Consult of 2,200 adults in the
U.S. found that 65% agree with the statement that &ldquo;companies should cut back on political donations to elected officials who are
working to limit access to abortion.&rdquo; (58% agreed with the statement that companies &ldquo;should oppose legislation to limit abortion
access.&rsquo;) (PDF available on request.)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">This pattern spending has drawn scrutiny from multiple news
sources, including <I>STAT, Bloomberg News, Huffington Post, The Minnesota Daily, CQ ESG Briefing </I>and <I>Forbes</I>. Links to those
articles are provided at the end of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD><B>Contributing to candidates and organizations blocking progress on climate change. </B><BR>
<BR>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Pfizer has committed to achieving science-based greenhouse
gas reduction targets yet is a member of the U.S. Chamber of Commerce, which has consistently lobbied to roll back specific US climate
regulations and promote regulatory frameworks that would slow the transition towards a low GHG emissions energy mix (see https://bit.ly/3EbL9va).
This raises questions about the extent to which Pfizer is also supporting electioneering efforts that conflict with its environmental
commitments. An analysis conducted by Bloomberg found that one-third of Pfizer&rsquo;s political spending in the 2020 election cycle supported
candidates characterized as &ldquo;ardent obstructionist[s] of proactive climate policy&rdquo; (see https://bloom.bg/3c7MwOU).<BR>
<BR>
</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD>In 2019, Popular.Info wrote about Pfizer&rsquo;s nearly $1 million in <B>contributions to</B> 52 <B>anti-LGBTQ politicians</B> in
the previous two years (see &ldquo;These 9 Pride-celebrating companies donated millions to anti-gay Congress members,&rdquo; LGBTQNation.com,
June 23, 2019 at https://bit.ly/3c8vfoQ). These donations conflict with Pfizer&rsquo;s aspirations to provide a supportive environment
for its LGBTQ employees.<BR>
<BR>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Supreme Court has interpreted the constitution as permitting political
spending by corporations, but it has also emphasized the rights of investors to use shareholder democracy to ensure accountability for
this spending. In our highly polarized and increasingly explosive political environment, <B>shareholders must insist upon a more responsible
and coherent political spending strategy</B>. We believe Pfizer&rsquo;s reputation is at risk, regardless of disclaimers asserting that
contributions do not imply an endorsement of all of the recipients&rsquo; views.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Why a YES Vote is Warranted: A Response to Pfizer&rsquo;s Opposition
Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The examples above illustrate vividly why we believe Pfizer is doing
a disservice to its shareholders and broader stakeholders by failing to align its political expenditures with its policies and values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pfizer&rsquo;s statement of opposition to our proposal mostly references
the Company&rsquo;s current governance and transparency mechanisms while evading the concerns raised in the proposal. The main arguments
advanced are that (1) current disclosures address the concerns raised in the proposal, and (2) contributions do &ldquo;not imply an endorsement
of a candidate&rsquo;s position on any social or religious issue.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Simply asserting that the Company does not endorse all of any candidate&rsquo;s
views is not equivalent to a statement by management explaining glaring incongruities and what, if anything, is being done to address
them.</U> Such a disclaimer does not negate or respond to investor concern about the existence and impact of incongruent contributions,
nor the need for an annual assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Nor has Pfizer published the analysis requested</U> in the proposal,
an &ldquo;annual report analyzing the congruency of political and electioneering expenditures during the preceding year against</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">publicly stated Company values and policies, with a further recommendation
that such report also contain management's analysis of risks to our Company's brand, reputation, or shareholder value of expenditures
in conflict with publicly stated Company values.&rdquo; We hasten to note that within the framework of the Resolved clause, it does not
rest with <I>investors</I> to determine which donations were incongruent; rather the Company should explain the basis for incongruency
of specific donations, and which overriding considerations cause it to provide and even perpetuate donations despite incongruent voting
records of any donation recipients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is worth noting that Pfizer&rsquo;s overall political spending transparency
and accountability mechanisms lag behind those of its industry peers, according to the 2020 CPA-Zicklin Index of Corporate Political Disclosure
and Accountability (see https://politicalaccountability.net/hifi/files/2020-CPA-Zicklin-Index.pdf). (Deficiencies noted in the CPA&rsquo;s
report concern failure to disclose trade association payments that may be used for political purposes; failure to disclose payments to
tax-exempt organizations like 501c4s that may be used for political purposes; failure to disclose a list of the amounts and recipients
of payments made by trade associations or other tax-exempt organizations of which it is a member; absence of a board committee that approves
political expenditures from corporate funds; and failure to publish a detailed report on a semiannual basis.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a recent speech, Acting SEC Allison Herren Lee Chair reaffirmed
the <U>salience of political spending disclosure to investment decision-making</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">[P]olitical spending disclosure
is inextricably linked to ESG issues. Consider for instance research showing that many companies that have made carbon neutral pledges,
or otherwise state they support climate-friendly initiatives, have donated substantial sums to candidates with climate voting records
inconsistent with such assertions. Consider also companies that made noteworthy pledges to alter their political spending practices in
response to racial justice protests, and whether, without political spending disclosure requirements, investors can adequately test these
claims, or would have held corporate managers accountable for those risks before they materialized. Political spending disclosure is key
to any discussion of sustainability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(&ldquo;A Climate for Change: Meeting Investor
Demand for Climate and ESG Information at the SEC,&rdquo; March 15, 2021 at https://bit.ly/3vXEH6D.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Pfizer&rsquo;s opposition statement evades the central issue raised
by our proposal: the risk of potential damage to Company reputation, shareholder value, and broader stakeholder interests</U> that steadily
accrues when corporate treasury and PAC dollars subsidize recipients whose activities undermine the Company&rsquo;s product lines and
its &ldquo;lived&rdquo; values of access to healthcare, environmental sustainability, diversity and inclusion, and other areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In an environment in which corporate political activity is closely
scrutinized by multiple stakeholders, we believe that Pfizer would be wise to incorporate these &ldquo;lived&rdquo; or implicit values
into its criteria for determining which recipients are eligible for political contributions. Pfizer is correct to consider recipients&rsquo;
capacity to further the Company&rsquo;s purpose &ldquo;to discover, develop and deliver breakthroughs that change patients&rsquo; lives&rdquo;--
but it is wrong to neglect those recipients&rsquo; responsibility for accelerating <I>harmful</I> breakthroughs (in anyone&rsquo;s lives),
such as those discussed above. Given the grievous damage to our democracy inflicted by the 30-plus members of Congress supported by Pfizer
who voted against certifying the presidential election results, it is insufficient to rest on the assertion that contributions &ldquo;do
not imply an endorsement of a candidate&rsquo;s position on any social or religious issue.&rdquo; <U>Shareholders should support this
proposal to signal that more accountability is warranted from Pfizer than this simple disclaimer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inconsistency can pose risk to corporate reputation, brand and market
share by leaving companies vulnerable to charges of hypocrisy or indifference to the environment or the social welfare of their employees
or the communities in which they operate. A recent survey of 2,200 global executives worldwide noted the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Corporate reputation is an invaluable asset with appreciable
impact on a Company&rsquo;s bottom line. On average, global executives attribute 63% of their Company&rsquo;s market value to their Company&rsquo;s
overall reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(See <I>The State of Corporate Reputation in 2020: Everything Matters
Now</I>, Weber Shandwick and KRC Research, 2020 at https://bit.ly/3rabGRw.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmaceutical companies especially need to pay close attention to
reputation. Prior to rising in public esteem during the pandemic, in 2019, the industry finished dead last in an annual Gallup poll asking
Americans for their views on 25 industries (see &ldquo;Pharma's reputation has soared during COVID-19 pandemic, poll finds,&rdquo; FiercePharma.com,
April 21, 2020 at https://bit.ly/318EsHm and &ldquo;Pharma sinks to new low&#8288;&mdash;and takes last place&#8288;&mdash;in consumer
sentiment poll,&rdquo; FiercePharma.com, September 4, 2019 https://bit.ly/3tIAYYv). These trends continued throughout the pandemic despite
the industry&rsquo;s record-setting development and distribution of Covid-19 vaccine. Between 2020 and 2021, pharma&rsquo;s positive approval
rating in the U.S. was only 31%, still at the bottom of Gallup&rsquo;s 25-industry ranking (https://news.gallup.com/poll/354653/image-ratings-several-industries-tumble.aspx).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We believe that the requested report will motivate Cigna to monitor
its political expenditures so that they do not erode shareholder value by diminishing the Company&rsquo;s reputation, consumer loyalty,
employee support and morale, brand, values, and corporate responsibility initiatives. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote &ldquo;Yes&rdquo; on this Shareholder Proposal No. 5.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>For questions, please contact Shelley Alpern at shelley@rhiaventures.org.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE FOREGOING INFORMATION MAY BE DISSEMINATED TO SHAREHOLDERS VIA TELEPHONE,
U.S. MAIL, E-MAIL, CERTAIN WEBSITES AND CERTAIN SOCIAL MEDIA VENUES, AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE OR AS A SOLICITATION
OF AUTHORITY TO VOTE YOUR PROXY. THE COST OF DISSEMINATING THE FOREGOING INFORMATION TO SHAREHOLDERS IS BEING BORNE ENTIRELY BY THE FILER
OF THIS SOLICITATION. PROXY CARDS WILL NOT BE ACCEPTED. PLEASE DO NOT SEND YOUR PROXY TO TARA HEALTH FOUNDATION. TO VOTE YOUR PROXY, PLEASE
FOLLOW THE INSTRUCTIONS ON YOUR PROXY CARD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Sources</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reports</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Funding the Bans, </I>Equity Forward, 2019 at https://bit.ly/3c6e9Ii</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Conflicted Consequences, </I>Center for Political Accountability,
2020 at https://bit.ly/3f4DPa0</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Bankrolling the Disenfranchisers,
</I>Public Citizen, 2021 at </FONT>https://bit.ly/3ra8Qfk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Political Spending &amp; Reproductive Health Rights</I>, Sustainable
Investments Institute, September 28, 2020 at https://bit.ly/2PeEnzh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>News sources</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Pharma contributed to attorneys general who want to repeal the
Affordable Care Act,&rdquo; STAT, October 20, 2020, at https://bit.ly/3cYD67O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These six corporations are financing the war on women in six
states,&rdquo; blog post, Popular.Info, May 20, 2019, at https://bit.ly/3se8xRP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Merck, Pfizer Back Lawmakers Who Oppose Company Products,&rdquo;
Bloomberg News, May 30, 2012, at https://bloom.bg/3tQovSN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;U.S. Businesses Say One Thing on Climate Change, But Their Campaign
Giving Says Another,&rdquo; Bloomberg Green, October 23, 2020, at https://bloom.bg/393c6CI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Contraceptive Makers Helped Elect Republican Congress Ready
To Defund Planned Parenthood,&rdquo; Huffington Post, March 2, 2017, at https://bit.ly/3vRWpID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Pharma contributions to politicians who support restricting
abortions could reverberate,&rdquo; STAT, July 24, 2019, at https://bit.ly/2Qvzt1y.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Dear AT&amp;T, Boeing, Pfizer, Comcast Walmart, Etc: Stop Funding
Abortion Attackers,&rdquo; Forbes.com, August 21, 2019, at https://bit.ly/2OZH9sv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These 9 Pride-celebrating companies donated millions to anti-gay
Congress members,&rdquo; LGBTQNation.com, June 23, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These are the Millionaire CEOs Whose Corporations Fund Politicians
Banning Abortions,&rdquo; LittleSis.org, May 29, 2019, at https://bit.ly/3c8vfoQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Corporations are Funding Politicians Who Support Abortion Bans,&rdquo;
MinnesotaDaily.com, June 12, 2019, at https://bit.ly/318YT72.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;CQ ESG Briefing,&rdquo; CQ Roll Call, April 22, 2021. No hyperlink
available; PDF available upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Where is the business backlash on Texas&rsquo;s abortion law?&rdquo;
Fortune.com, September 2, 2021 at https://fortune.com/2021/09/02/texas-abortion-law-business-backlash-match-group-bumble-sb8/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Speeches</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;A Climate for Change: Meeting Investor Demand for Climate and
ESG Information at the SEC,&rdquo; Acting SEC Commissioner Allison Herren Lee, March 15, 2021, at https://bit.ly/3vXEH6D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tara_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tara_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[])9HH$,DTB11J"6>1@B*!R2S,0J@=R2!5'^V-)_Z"FG_C>6X_
M3S*AUT Z;< C(V<CU^9>*TPG ^4?]\)_C5I1Y4Y7NY-:::+EUV??\#-RFYN,
M>5))/5-[^C13_M?2?^@G8?\ @7!_\<IO]M:1T_M.P]?^/J#^>_'X52UG7-!\
M/Z;?ZOK6I66E:7I=G<7^I:A?316UK8V=JGFW$\\LH"1I'&&<ECCY=O4BO-?#
M?Q?\*>/] MM9\ 7J:M]LDN8,7=O<:?)I#VDGEW$NMV=W!#=:=Y2E;A(;J**2
M>"6VGC!@GCD;@>99:LQH90\;A8YIB<-6QE#+ZF*HTL74P>'E"-?%PH2O5GAZ
M+G%5)QARW:2E=-&TL/CE@JN8K#5I8&AB*6%K8NGAZM3#PQ%:,JE/#2JIJG"M
M4IPJ3C&4M(0E4E'EU/5QK.CG(&J:><$ XO+?@D @']YU((('<$'H0:/[9TCG
M_B:6''_3W!^GS\_A7D6F:D+"ZDN=*N;W4Y&9YM2M+V/R_P"W8P6,VIZ-N!VR
M6S!D6#[CP1JH"\9EF^.'PQMO&6C> KCQ/91>*-=M/M%GI[)(4BFDCFEM--O[
MM8&M=/U?4X[6^ETG3+N>*\U6+3;^6QBE2W<C3-L?EN2+#5,SQV%P-'%8REEU
M">-Q%/"JMF.)_P!UP--U%9XBORU'"G\35-M1>MN?*EC,Y]M3P.%J8C$8?#UL
M57I8>E5KJAAL/RO$8FHZ2E^XPR:]O+10<H\THW5_6?[8TC_H*:?_ .!EO_\
M'*?'JFF3.D<6H6<LDA(2..YA=W(!)"HKEB<*QX'0$]J>)H&X#+_#_P LP/O_
M '>OKQ^8]1FAJ*@2:7Q@_P!I1C[O;[+>-Z>JCW]*ZTZ;;BN;F5KI--JZYE=<
MMU?IW6JT'>HH\UX._*XOEDDU*SO=R=[III[:FW7F_B;XQ?";P7J(TCQA\3/
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MOZ=-);S1QWUGX\\5/=6CO&0MQ;I>ZA>V;31$AXQ<6MQ$64"2*1"R'XV_8O\
MV1/&7[(G_!0S7/"=]]OUGP'K?PI\5:EX"\9&W9(]8T0>(?#:MI^IM&AM;?7]
M(E=+;5+.*11(HAU.&)+.]MTC\>&0\$8_+LZKY5Q)FJS'*\NEC\/@<TRS"X7^
MT7"I3A*AAZE#'8B/M(QFZC4I*3C%\L6DVOH*G%WBAE&=\,83/^#>'99-GV=X
M?)L7F61YWF6.K93+%TZLJ.)Q.'K931BJ+J4O9J4IQISG)0G4H64I_P! =-=M
MJECP ,DD''Z G\A3J^;_ -K'XYV7[//P!^)?Q4F\N>_\.^'I8_#MDZEEO_%6
MK2Q:3X;M74$.]LVLWUA)?!/F6P2ZE7/E,*^&P.#Q&8XS"X#"4W5Q6-Q%'"X>
MFMYUL14C2I1ZV3G)7>R5WLC]8S+,,-E67X[,\;45+"9?A,1C<34>T:.%HSKU
M7TNU"$FDM6]%J>K^%/B;\/O'6J>*M$\'>,O#OB;5_ ^K-H7C#3=&U2UO[SPW
MK"O<1'3=9M[>1Y+&[\RTNHQ#.$8O;S(!NB<#N:_DA_X)H_'WQ/\  _\ :_M?
M#WQ'GU*PL/CFUOH'B[^W4DMKQ?$WB14\1^"?$=XD^&-SJ-[J4%MY[QJKV7BB
M>[7=OR?ZUXIXY ,,">!@9ZD9QR ?;D#.,@ $5];Q]P=/@K.*6 6*6.P6*P.&
MQF$QT;<E92@H8F*<4H_NL2II6U5.=)3;GS-_GGA/XCTO$OAW$9M+"++L?@LU
MQF78[+[RYJ"C4E6P$VIRE.]; 3I>T<K*6)I8KDC&$5&,]96M:[HOAO3+O6O$
M.KZ;H6CV"++?:KK%];:;IMG&\B1+)=7UY)#;6Z-+)'&K2RH&D=4!+$"M6N4\
M;^#?"_Q \*:YX-\::%IWB7POXAL7T_6M#U:W6ZT_4+.1D9HIX6ZE'1)89$*2
MP3(DT+QRHKCXNE[+VE/V[J1H<\/;2I1C*K&ES+VCIQG*$)5%"[A&4HQ<K*4D
MKM?I==UU0K/#*E+$JE4^KQKN<:+K\C]DJTH*4XTG4Y54<(N2A=Q3=D<?_P +
M]^!?3_A<OPMSQ\O_  GWA;=R,CY?[5W<CGI2?\+_ /@5_P!%F^%G_A?^%?\
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M#,*26)QN,KSIT(5,'C_WU)8R$\+AH82A.LZN#C@XO)LPP&(RO$PJ99PWP&\
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M+:7=W/8_"I]$\<>'W*H+CPSXRLM/FU'3KFW!CCE-S9\6@TV6[Z7X-3^#8/\
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+,8Q2C%))))(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
